71 related articles for article (PubMed ID: 18661432)
1. Resolution in PET hypoxia imaging: voxel size matters.
Busk M; Horsman MR; Overgaard J
Acta Oncol; 2008; 47(7):1201-10. PubMed ID: 18661432
[TBL] [Abstract][Full Text] [Related]
2. Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast?
Busk M; Horsman MR; Jakobsen S; Hansen KV; Bussink J; van der Kogel A; Overgaard J
Radiother Oncol; 2009 Sep; 92(3):429-36. PubMed ID: 19729214
[TBL] [Abstract][Full Text] [Related]
3. Dual-tracer PET of viable tumor volume and hypoxia for identification of necrosis-containing radio-resistant Sub-volumes.
Busk M; Horsman MR; Overgaard J; Jakobsen S
Acta Oncol; 2019 Oct; 58(10):1476-1482. PubMed ID: 31432722
[No Abstract] [Full Text] [Related]
4. Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET.
Busk M; Munk OL; Jakobsen S; Wang T; Skals M; Steiniche T; Horsman MR; Overgaard J
Acta Oncol; 2010 Oct; 49(7):922-33. PubMed ID: 20831479
[TBL] [Abstract][Full Text] [Related]
5. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy.
Busk M; Horsman MR; Jakobsen S; Keiding S; van der Kogel AJ; Bussink J; Overgaard J
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1202-12. PubMed ID: 18313528
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia positron emission tomography imaging: combining information on perfusion and tracer retention to improve hypoxia specificity.
Busk M; Munk OL; Jakobsen SS; Horsman MR
Acta Oncol; 2017 Nov; 56(11):1583-1590. PubMed ID: 28840765
[TBL] [Abstract][Full Text] [Related]
7. Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode Po2 measurements in murine tumors.
Sørensen M; Horsman MR; Cumming P; Munk OL; Keiding S
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):854-61. PubMed ID: 15936570
[TBL] [Abstract][Full Text] [Related]
8. In vivo identification and specificity assessment of mRNA markers of hypoxia in human and mouse tumors.
Busk M; Toustrup K; Sørensen BS; Alsner J; Horsman MR; Jakobsen S; Overgaard J
BMC Cancer; 2011 Feb; 11():63. PubMed ID: 21306648
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine.
Beck R; Röper B; Carlsen JM; Huisman MC; Lebschi JA; Andratschke N; Picchio M; Souvatzoglou M; Machulla HJ; Piert M
J Nucl Med; 2007 Jun; 48(6):973-80. PubMed ID: 17536108
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer.
Grosu AL; Souvatzoglou M; Röper B; Dobritz M; Wiedenmann N; Jacob V; Wester HJ; Reischl G; Machulla HJ; Schwaiger M; Molls M; Piert M
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):541-51. PubMed ID: 17869667
[TBL] [Abstract][Full Text] [Related]
11. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography.
Aboagye EO; Kelson AB; Tracy M; Workman P
Anticancer Drug Des; 1998 Sep; 13(6):703-30. PubMed ID: 9755726
[TBL] [Abstract][Full Text] [Related]
12. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio.
Lehtiö K; Oikonen V; Nyman S; Grönroos T; Roivainen A; Eskola O; Minn H
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):101-8. PubMed ID: 12483416
[TBL] [Abstract][Full Text] [Related]
13. A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia.
Thorwarth D; Eschmann SM; Paulsen F; Alber M
Phys Med Biol; 2005 May; 50(10):2209-24. PubMed ID: 15876662
[TBL] [Abstract][Full Text] [Related]
14. Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.
Troost EG; Laverman P; Kaanders JH; Philippens M; Lok J; Oyen WJ; van der Kogel AJ; Boerman OC; Bussink J
Radiother Oncol; 2006 Aug; 80(2):157-64. PubMed ID: 16905213
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumor lactate oxidation: consequences for the tumor microenvironment.
Busk M; Walenta S; Mueller-Klieser W; Steiniche T; Jakobsen S; Horsman MR; Overgaard J
Radiother Oncol; 2011 Jun; 99(3):404-11. PubMed ID: 21704401
[TBL] [Abstract][Full Text] [Related]
16. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
17. BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors.
Melo T; Duncan J; Ballinger JR; Rauth AM
J Nucl Med; 2000 Jan; 41(1):169-76. PubMed ID: 10647620
[TBL] [Abstract][Full Text] [Related]
18. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia.
Yang DJ; Wallace S; Cherif A; Li C; Gretzer MB; Kim EE; Podoloff DA
Radiology; 1995 Mar; 194(3):795-800. PubMed ID: 7862981
[TBL] [Abstract][Full Text] [Related]
19. Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone).
Lewis JS; Herrero P; Sharp TL; Engelbach JA; Fujibayashi Y; Laforest R; Kovacs A; Gropler RJ; Welch MJ
J Nucl Med; 2002 Nov; 43(11):1557-69. PubMed ID: 12411560
[TBL] [Abstract][Full Text] [Related]
20. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography.
Matsumoto K; Szajek L; Krishna MC; Cook JA; Seidel J; Grimes K; Carson J; Sowers AL; English S; Green MV; Bacharach SL; Eckelman WC; Mitchell JB
Int J Oncol; 2007 Apr; 30(4):873-81. PubMed ID: 17332926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
